🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Lacolle Peters

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial”.

Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial

The Lancet Haematology(2022)10.1016/s2352-3026(22)00318-0
N/A
1.4DataRank · unranked
41 citations

Lu Chen, Yago Nieto, Leona Holmberg, Patrick B. Johnston, Matthew Mei +20 more

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood(2023)10.1182/blood.2023020485
N/A
1.3DataRank · unranked
40 citations

Lu Chen, James Godfrey, Joo Y. Song, Colt A. Egelston, Sandrine Puverel +18 more

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study

The Lancet Haematology(2024)10.1016/s2352-3026(24)00171-6
N/A
0.673DataRank · unranked
20 citations

Jasmine Zain, Kerry J. Savage, Tatyana Feldman, Jonathan E. Brammer, Lu Chen +14 more

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma

Haematologica(2023)10.3324/haematol.2023.283002
N/A
0.599DataRank · unranked
19 citations

Matthew Mei, Lu Chen, Joo Y. Song, Victoria Bedell, Elizabeth Budde +13 more

Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma

HemaSphere(2025)10.1002/hem3.70126
N/A
0DataRank · unranked
8 citations

Joycelynne Palmer, Hun Ju Lee, Iris Isufi, Robert Chen, Ni‐Chun Tsai +13 more